بدائل البحث:
significant treatment » significant investment (توسيع البحث), significant enrichment (توسيع البحث), significant impairment (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
treatment decrease » treatment decreased (توسيع البحث), treatments decreased (توسيع البحث), treatment increases (توسيع البحث)
significant treatment » significant investment (توسيع البحث), significant enrichment (توسيع البحث), significant impairment (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
treatment decrease » treatment decreased (توسيع البحث), treatments decreased (توسيع البحث), treatment increases (توسيع البحث)
-
1281
-
1282
-
1283
-
1284
The TOR inhibitors Rapamycin and AZD-8055 strongly reduce RPS6 phosphorylation and cell proliferation in Vasa2+/Piwi1+ cells.
منشور في 2025"…Compared to 0.2% DMSO-treated controls, Rap (G, H) and AZD (I, J) treatment leads to a reduced EdU index regardless of starvation history, concentration, or incubation time. …"
-
1285
-
1286
-
1287
-
1288
Prime sequences.
منشور في 2025"…In this study, we found that microRNA-129-5p (miR-129-5p) was significantly decreased in the brains of depressive mice. …"
-
1289
-
1290
-
1291
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1292
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1293
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1294
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1295
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1296
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1297
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1298
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
منشور في 2025"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"
-
1299
-
1300